PD-1/PD-L1-IN-27

Cat. No.:	HY-146740
CAS No.:	2891831-47-1
Molecular Formula:	$C_{44}H_{35}NO_6$
Molecular Weight:	673.75
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PD-1/PD-L1-IN-27 is a potent PD-1/PD-L1 inhibitor with an IC_{50} value of 134 nM. PD-1/PD-L1-IN-27 shows antitumor effects with low T cell cytotoxicity. PD-1/PD-L1-IN-27 has the ability to activate $CD8^+$ T cells and reduces T cell exhaustion[1].
IC_{50} & Target	IC_{50}: 134 nM (PD-1/PD-L1)[1]

In Vitro

PD-1/PD-L1-IN-27 (compound MZ58) (2.5, 5, 10, 50 μM; 48 h) shows antitumor effects with low T cell cytotoxicity[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line:	MDA-MB-231 cells
Concentration:	2.5, 5, 10, 50 μM
Incubation Time:	48 h
Result:	Facilitated cell proliferation with low T cell cytotoxicity.

In Vivo

PD-1/PD-L1-IN-27 (10, 25 mg/kg; i.g.) shows antitumor effecct[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	20-22 g, 6-8 weeks, male C57BL/6J mice (MC 38 cell lines)[1]
Dosage:	10, 25 mg/kg
Administration:	I.g.
Result:	Showed antitumor effecct.

REFERENCES

[1]. Zhang M, et al. Molecular hybridization used to design and synthesize neo-tanshinlactone derivatives as PD-1/PD-L1 inhibitors. Bioorg Med Chem. 2022; 54:116579.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA